Author

E. S. Theel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:virus· 1

Frequent Co-Authors

D. H. Fremont· 2 shared H. Zhao· 2 shared L.-M. Bloyet· 2 shared M. S. Diamond· 2 shared P. W. Rothlauf· 2 shared R. E. Chen· 2 shared S. P. J. Whelan· 2 shared Z. Liu· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

D. H. Fremont

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration

S. Fiedler, S. R. A. Devenish, A. S. Morgunov, A. Ilsley, F. Ricci, M. Emmenegger, V. Kosmoliaptsis, E. S. Theel, J. R. Mills, A. M. Sholukh, A. A. A. Aguzzi, A. Iwasaki, A. K. Lynn, T. P. J. Knowles

The paper links antiviral activity of therapeutic antibodies to their affinity and concentration by comparing them to serological fingerprints in convalescent sera.

bioRxiv · Feb 3, 2022Biochemistry

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Z. Liu, L. A. VanBlargan, L.-M. Bloyet, P. W. Rothlauf, R. E. Chen, S. Stumpf, H. Zhao, J. M. Errico, E. S. Theel, M. J. Liebeskind, B. Alford, W. J. Buchser, A. H. Ellebedy, D. H. Fremont, M. S. Diamond, S. P. J. Whelan

bioRxiv · Nov 6, 2020 · PreprintMicrobiology

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

J. B. Case, P. W. Rothlauf, R. E. Chen, Z. Liu, H. Zhao, A. S. Kim, L.-M. Bloyet, Q. Zeng, S. Tahan, L. Droit, M. X. G. Ilagan, M. A. Tartell, G. K. Amarasinghe, J. P. Henderson, S. Miersch, , S. P. J. Whelan

This study develops two neutralization assays for SARS-CoV-2 using VSV and a clinical isolate, showing high concordance between monoclonal, polyclonal antibodies, and ACE2-Fc in neutralizing activity.

bioRxiv · May 18, 2020Microbiology